Cannabis use disorder: from neurobiology to treatment.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
15 Oct 2024
Historique:
medline: 15 10 2024
pubmed: 15 10 2024
entrez: 15 10 2024
Statut: epublish

Résumé

Cannabis has been legalized for medical and recreational purposes in multiple countries. A large number of people are using cannabis and some will develop cannabis use disorder (CUD). There is a growing recognition that CUD requires specific interventions. This Review will cover this topic from a variety of perspectives, with a particular emphasis on neurobiological findings and innovative treatment approaches that are being pursued. We will first describe the epidemiology and burden of disease of CUD, including risk factors associated with CUD (both in terms of general risk and genetic risk variants). Neurobiological alterations identified in brain imaging studies will be presented. Several psychosocial interventions that are useful for the management of CUD, including motivational enhancement therapy, behavioral and cognitive therapy, and contingency management, will be covered. Although no pharmacological interventions are yet approved for CUD, we present the most promising pharmacological interventions being tested.

Identifiants

pubmed: 39403927
pii: 172887
doi: 10.1172/JCI172887
doi:
pii:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Bernard Le Foll (B)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Institute of Medical Sciences.
Department of Psychiatry, and.
Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.

Victor M Tang (VM)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Institute of Medical Sciences.
Department of Psychiatry, and.

Sergio Rueda (S)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Institute of Medical Sciences.
Department of Psychiatry, and.

Leanne V Trick (LV)

Department of Psychology, Durham University, Durham, United Kingdom.

Isabelle Boileau (I)

Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Institute of Medical Sciences.
Department of Psychiatry, and.
Brain Health Imaging Centre, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH